An interventional study of AI chatbot-enabled nurse-led program. and Usual Care in Cardiovascular-kidney-metabolic Syndrome, sponsored by Taipei Medical University. Not yet recruiting at 1 site in Taiwan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Taipei Medical University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Metabolic Syndrome with a site in Taiwan — 15 open to participants now, 15 under way, none of them phase 3. Metabolic Syndrome · Taiwan.
Among the 69 studies in Metabolic Syndrome with a site in Taiwan, this one is the 18th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2026, is one of 32 with no phase, reaches primary completion later than 7 of the 14 other live ones, and was the 65th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →15 of the 69 studies in Metabolic Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:
Tri-Service General Hospital (TSGH) · Sites in Taiwan
Ages 20–65
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+
Taipei Medical University · Sites in Taiwan
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2 · Phase 4 5
First in 2004; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 80 across the 40 interventional studies, 295 across the 28 observational. Of the 34 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 69 have an industry lead sponsor. The 10 most frequent:
Taipei Medical University is the lead sponsor of 258 studies on the registry; 59 are open to participants now.
Taipei Medical University has 3 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Metabolic Syndrome with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07229521Taipei Medical UniversityEffects of Nattokinase on Cardiovascular Risk, Gut Microbiota, Sleep, and Cognition in Metabolic Syndrome With Sleep Disorders. | 2026-12-11 |
| NCT07239167National Taiwan University HospitalA Prospective Cohort Study on Patient With Obesity Undergoing Weight Change | 2027-04-08 |
| NCT05956379National Taiwan University HospitalChronic Hepatitis B Patients With Concurrent MAFLD: Cohort Study and Exercise Intervention. | 2027-07-31 |
| NCT07577284Taipei Medical UniversityAI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome | 2027-07-31 |
| NCT06271200National Health Research Institutes, TaiwanStrategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET) | 2027-10-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Metabolic Syndrome with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial will evaluate the effectiveness of an AI chatbot-enabled electronic patient-reported outcome (ePRO) monitoring and nurse-led self-management intervention for adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. A total of 80 participants will be randomly assigned to either the intervention or control group and followed for 6 months. Participants in the intervention group will complete weekly ePRO assessments through an AI-enabled platform and receive individualized feedback, self-management support, and nurse-led clinical follow-up when indicated. Participants in the control group will receive usual care and complete weekly ePRO assessments through a non-AI platform without automated feedback or structured nurse-led support. Outcomes will be assessed at baseline, 3 months, and 6 months and will include patient-reported health outcomes, patient activation, health literacy, healthcare utilization, and changes in CKM syndrome stage.
This two-arm, parallel-group randomized controlled trial will evaluate the effectiveness of an AI chatbot-enabled electronic patient-reported outcome (ePRO) monitoring and nurse-led self-management intervention for adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. A total of 80 adults aged 40 years or older with stage 1 or stage 2 CKM syndrome will be recruited from one tertiary hospital in Northern Taiwan and followed for 6 months. Participants will be randomly assigned in a 1:1 ratio using computer-generated permuted block randomization with randomly varying block sizes of 4 and 6 and allocation concealment.
Participants in the intervention group will receive usual outpatient care plus an AI chatbot-enabled ePRO monitoring and nurse-led self-management intervention. The AI-enabled platform will support weekly ePRO monitoring, individualized feedback, self-management support, and risk identification. Nurses will review clinically significant alerts and provide individualized support, care coordination, and clinical escalation when indicated.
Participants in the control group will receive usual outpatient care and complete weekly ePRO assessments through a non-AI platform without automated feedback, individualized recommendations, risk alerts, or nurse-led follow-up based on their weekly ePRO responses.
Primary outcomes include the seven PROMIS-29 domain-specific T-scores and the 0-10 Pain Intensity score. Secondary outcomes include patient activation, health literacy, healthcare utilization, and changes in CKM syndrome stage. Patient-reported health outcomes, patient activation, health literacy, and CKM syndrome stage will be assessed at baseline, 3 months, and 6 months, while healthcare utilization will be assessed prospectively over the 6-month follow-up period, with data collected at 3 and 6 months and updated through interim participant reports.
The criteria were revised on the registry on Oct 5, 2026. See what changed
***Inclusion Criteria***
***Exclusion Criteria***
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive usual outpatient care plus a 6-month AI chatbot-enabled ePRO monitoring and nurse-led self-management program, including weekly ePRO assessments, individualized feedback, self-management support, risk alerts, and nurse-led follow-up when indicated.
Other: AI chatbot-enabled nurse-led program.
Participants will receive usual outpatient care and complete weekly ePRO assessments through a non-AI platform without automated feedback, individualized recommendations, risk alerts, or structured nurse-led support based on their weekly ePRO responses.
Other: Usual Care
Participants in the intervention group will receive a six-month nurse-led, AI chatbot-enabled symptom monitoring and self-management program integrating weekly ePRO assessments. The intervention begins with a structured nurse-led intake session including CKM assessment, symptom review, goal setting, and training on chatbot use. Participants complete weekly PROMIS-29 v2.1 assessments via a smartphone-based chatbot, which provides automated, rule-based feedback, self-management guidance, and motivational prompts. A risk-stratification algorithm generates alerts when symptom deterioration is detected. Nurses review alerts daily and provide follow-up via messaging, teleconsultation, or referral depending on severity, with same-day escalation for high-risk symptoms.
Usual care based on standard outpatient follow-up, without access to the AI chatbot or nurse-led coordination
PROMIS-29 v2.1 Domain-Specific T-Scores and Pain Intensity
The PROMIS-29 v2.1 Traditional Chinese version will be used to assess seven health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. Each domain contains four items and will be scored separately and converted to standardized T-scores with a reference-population mean of 50 and standard deviation of 10. Higher T-scores indicate greater symptom burden for Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, whereas higher T-scores indicate better health for Physical Function and Ability to Participate in Social Roles and Activities. Pain Intensity will be assessed separately using a single 0-10 numeric rating scale, with higher scores indicating greater pain intensity.
Time frame: Baseline, 3 months, and 6 months
Patient Activation Measure-13 (PAM-13)
Patient activation will be assessed using the 13-item Patient Activation Measure (PAM-13), which evaluates individuals' knowledge, skills, and confidence in managing their health. Items are rated on a 5-point response scale, including a "not applicable" option. Raw scores are converted to a 0-100 scale, with higher scores indicating greater patient activation.
Time frame: Baseline, 3 months, and 6 months.
Mandarin Multidimensional Health Literacy Questionnaire (MMHLQ)
Health literacy will be assessed using the 20-item Mandarin Multidimensional Health Literacy Questionnaire (MMHLQ), which covers five domains: obtaining, understanding, evaluating, and applying health information, as well as communication and interaction. Each item is rated on a 4-point scale from very difficult to very easy. Scores are transformed to a 0-50 scale, with higher scores indicating better health literacy. Scores are categorized as insufficient (0-25), limited (\>25-33), sufficient (\>33-42), and excellent (\>42-50).
Time frame: Baseline, 3 months, and 6 months.
Healthcare Utilization
Healthcare utilization will be assessed prospectively based on participant self-report of the number of emergency department visits and hospitalizations occurring during each follow-up interval. Participants will also be encouraged to report such events through the study platform between scheduled assessments.
Time frame: Enrollment to 3 months and 3 months to 6 months
Change in CKM Syndrome Stage
CKM syndrome stage will be assessed using available clinical and laboratory information and participant-reported updates. Changes from baseline will be categorized as progression to a more advanced CKM syndrome stage or improvement to a lower stage.
Time frame: Baseline, 3 months, and 6 months
Plan to share: No — Individual participant data (IPD) will not be publicly shared due to ethical and privacy considerations. However, de-identified datasets may be made available to qualified researchers upon reasonable request after publication, subject to approval by the corresponding author and the Institutional Review Board (IRB) of Taipei Medical University. Data sharing will comply with institutional policies and applicable data protection regulations
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 9 months is below that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
Start moved once since we started tracking on Sep 25, 2026: May 2026 → Oct 2026, on Oct 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.